Drug intelligence / Profile preview

PVP-2a

Development stage: Preclinical
Lead developer: Aveiro University
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems

Overview

PVP-2a is an experimental polyvinylpyrrolidone micellar formulation containing the neutral benzoporphyrin photosensitizer designated 2a. Upon light activation, the benzoporphyrin component produces reactive oxygen species, including singlet oxygen, to induce photodynamic cytotoxicity. It was evaluated in vitro against HT-1376 human bladder cancer cells as a potential photodynamic-therapy agent; it is not a marketed medicine and has no assigned INN. ([mdpi.com](https://www.mdpi.com/1420-3049/26/17/5312/xml))

Other names: PVP-2aPVP2aPVP 2a

Beyond the preview

Go deeper on PVP-2a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PVP-2a.

Explore the full profile